Aspira Women’s Health Inc. to Report First Quarter 2021 Financial Results on May 13
Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its first-quarter financial results for the period ending March 31, 2021, on May 13, 2021, after market close. A conference call and webcast will be held at 4:30 p.m. ET the same day, with domestic and international dial-in numbers provided for investor participation.
The company focuses on innovative testing options and bio-analytical solutions aimed at improving women's health outcomes, including addressing ethnic disparities in ovarian cancer risk assessment.
- Highlights focus on innovative testing for women's health.
- Commitment to closing ethnic disparity gaps in ovarian cancer risk assessment.
- None.
AUSTIN, Texas, May 05, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the first quarter ended March 31, 2021 on Thursday, May 13, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Thursday, May 13 at 4:30 pm ET | |
| Domestic: | 877-407-4018 |
| International: | 201-689-8471 |
| Conference ID: | 13719197 |
| Webcast: | http://public.viavid.com/index.php?id=144631 |
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com
FAQ
When will Aspira Women’s Health report its Q1 financial results?
What time is the conference call for Aspira Women’s Health's Q1 results?
What is the significance of OVA1® plus for Aspira Women’s Health?
What is Aspira Women’s Health's focus in women's health?
